EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates

Patrick M Glassman iD

Cancers · 19.12.2025 · 18 (1) · 5

DOI: 10.3390/cancers18010005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.12.2025. Verfasst von Patrick M Glassman. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) have risen in prominence over the past 15 years, with numerous regulatory approvals in oncology. A complicating factor in the development of ADCs is the presence of numerous analytes with unique pharmacologic properties. Following administration, ADCs are present in the body as the intact ADC, unconjugated antibody, and liberated payload. Due to heterogeneity in conjugation and in vivo deconjugation rates, the drug-to-antibody ratio (DAR) changes with time. Each of these molecular species has unique pharmacokinetic (PK) and pharmacodynamic (PD) properties that should be understood and characterized. One approach that is frequently applied is the development of in silico mathematical models to characterize and predict the PK/PD of ADCs. In this review, we summarize key mechanisms controlling the PK/PD of ADCs. This provides context for a detailed discussion of the array of PK/PD models that have been applied for ADCs, ranging from empirical compartmental models all the way through system-level models, such as physiologically based pharmacokinetics (PBPK) and cell-level PK/PD models. We provide a critical discussion of the strengths, weaknesses, and utility of each of these model structures.

Schlagwörter

Stichwörter der Autor:innen

PK/PD modelingantibody-drug conjugatespharmacodynamicspharmacokinetics

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, PA 19140, USA.

ORCID-Profile: Patrick M Glassman

Zitieren

APA

Glassman, P. M. (2025). Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates. Cancers, 18(1), 5. https://doi.org/10.3390/cancers18010005

Vancouver

Glassman PM. Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates. Cancers. 2025;18(1):5. doi:10.3390/cancers18010005

BibTeX
@article{Glassman2025,
  author = {Glassman, Patrick M},
  title = {Pharmacokinetic and Pharmacodynamic Modeling of Antibody-Drug Conjugates},
  journal = {Cancers},
  year = {2025},
  volume = {18},
  number = {1},
  pages = {5},
  doi = {10.3390/cancers18010005}
}
Kostenlos starten →